PB
Paradigm Biopharmaceuticals Limited
PBIGF · OTC
$0.18 -3.16% (-$0.01)
1M +84.00%
Market Cap $159.0M
P/E Ratio -
Div. Yield -
ROE 347.77%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 1,987.14x
P/B 45.89x
P/E N/A
Growth
0 /100
Declining Book val. growth 59.88%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 102.77%
Net margin 70,283.80%
FCF margin 54,507.20%
Quality
0 /100
Poor ROIC 484.07%
ROE 347.77%
Asset turnover 0.00x
Debt
17 /100
High Debt/Equity 2.16x
Current ratio 1.10x
Int. coverage -24.83x
Stability
19 /100
Unstable Beta -0.02x
EPS volatility 121.06%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre PBIGF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul John Rennie
Employees
8
Headquarters
Melbourne
Evenimente viitoare
24 FEB.
Earnings
Upcoming earnings report